Group 1: Company Overview - The main product of Shanxi Zhendong Pharmaceutical Co., Ltd. is primarily for internal use, with a small portion sold externally, mainly through direct contact with manufacturers, rather than through the herbal market [2] - The company is exploring the U.S. market for its traditional Chinese medicine products, as there are approximately 6,000 TCM research institutions in the U.S., with around 4,000 requiring imports of Chinese extracts [2] Group 2: Product Development and Sales - The company aims to diversify its product line beyond its main product, Yanshu, which has limited usage; it plans to increase investment in secondary products like Bicalutamide and Pemetrexed Disodium to drive growth [3] - Currently, the company has over 1,000 sales personnel, focusing on self-sales of core products [3] Group 3: Mergers and Acquisitions - The company is actively seeking suitable merger and acquisition targets, having established a new investment team to identify quality opportunities [3] Group 4: International Collaboration - The company has established a research office in collaboration with the National Academy of Traditional Chinese Medicine at the U.S. National Cancer Institute to promote TCM in cancer treatment [4] - It is a member of the International TCM Cancer Treatment Alliance, aiming to accelerate research and promotion of traditional Chinese medicine [4] - The company signed a cooperation agreement for EU registration of its compound TCM products, marking its entry into the European market [4] Group 5: Research Achievements - Recent research by the company, in collaboration with the Guang'anmen Hospital of the China Academy of Chinese Medical Sciences and the U.S. National Cancer Institute, has demonstrated the efficacy of its compound Ku Shen injection in treating cancer pain, published in a prominent international oncology journal [5] - The Yanshu compound Ku Shen injection is effective in inhibiting cancer pain, bleeding, and tumor growth, and is widely used in cancer treatment [5]
振东制药(300158) - 2014年12月9日投资者关系活动记录表